Repare Therapeutics 株価情報 (NASDAQ: RPTX)

最新ニュース Repare Therapeutics (NASDAQ:RPTX) 株価情報

REPARE THERAPEUTICS INC

Repare Therapeutics

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Repare Therapeutics Inc

Benchmark analyst Mike Hickey maintains National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) with a Buy and lowers the price target from $8 to $7.

News

Price Target

Analyst Ratings

NCMI

Benchmark Maintains Buy on National CineMedia, Lowers Price Target to $7

Business Outlook
Our business outlook for the fiscal year ending May 31, 2026 ("fiscal 2026") incorporates current assumptions and market conditions and excludes acquisition-related costs. Changes in the macroeconomic environment could alter our guidance. With consideration of these impacts, we have updated our business outlook as follows:
<ul>
<li>Total revenue is anticipated to grow in the range of 16.5% to 18.5%.</li>
<li>Adjusted diluted earnings per share(1) is anticipated to grow in the range of 8.5% to 10.5%.</li>
<li>Management Solutions revenue is anticipated to grow in the range of 20.0% to 22.0%.</li>
<li>PEO and Insurance Solutions revenue is anticipated to grow in the range of 6.0% to 8.0%.</li>
<li>Interest on funds held for clients is expected to be in the range of $190 million to $200 million.</li>
<li>Adjusted operating margin(1) is anticipated to be approximately 43%.</li>
<li>The effective income tax rate for fiscal 2026 is anticipated to be in the range of 24% to 25%.</li>
</ul>

Guidance

PAYX

CORRECTION: Paychex FY26 Outlook: Adj EPS $5.40-$5.50 vs $5.31 Estimate; Sales $6.49B-$6.60B vs $6.36B Estimate

American investor and entrepreneur, Anthony Pompliano, today announced that ProCap BTC, LLC, a bitcoin-native financial services firm (the "Company"), has purchased 1,208 bitcoin at a time weighted average price ("TWAP") of $105,977 per bitcoin, following the Company's June 23, 2025 announcement of a proposed $1 billion business combination with Columbus Circle Capital Corp. I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCM#NASDAQ">CCCM</a>) to take the Company public as ProCap Financial, Inc. The Company now holds 4,932 bitcoin on its balance sheet.&nbsp;
The bitcoin was acquired as part of the Company's on-going bitcoin purchase program. The Company has wasted no time delivering for its investors by deploying the funds raised at signing to accumulate bitcoin. As a result, equity investors received immediate bitcoin exposure from the equity raise.
The Company plans to continue buying bitcoin for its balance sheet as part of its ongoing business strategy. At the closing of the proposed business combination, ProCap Financial is expected to hold up to $1 billion in bitcoin on its balance sheet.&nbsp;The TWAP for the Day 2 purchases may be different from the "Signing Bitcoin Price" for purposes of Business Combination Agreement signed by CCCM and the Company on June 23, 2025.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

CCCM

ProCap BTC Acquires 1,208 Bitcoin At $105,977 Each; Now Holds 4,932 Bitcoin On Its Balance Sheet

Cycurion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) ("Cycurion" or the "Company"), a trusted leader in IT cybersecurity solutions and AI, announces the award of several new contracts totaling over $8 million. These agreements, secured with government and commercial clients, reinforce Cycurion's position as a trusted partner in protecting critical digital infrastructure.
The contracts, spanning program management, cybersecurity, and disaster recovery services, include a significant $6 million agreement with a major municipal transportation agency to deliver comprehensive IT and cybersecurity solutions. Over $1 million of the total contract value will begin billing in June 2025, with the remainder commencing in the third quarter of 2025. These engagements are set to run for the next 12 to 18 months, leveraging Cycurion's proprietary ARx platform for real-time threat detection and multi-layered protection.

Contracts

CYCU

Cycurion Bags Over $8M In New Contracts From Government And Commercial Clients, Strengthening Cybersecurity Footprint

WIIM

ECARX Holdings shares are trading higher after the company announced it signed a partnership with a global developer of robotic lawn mowers to integrate its lidar solution.

Manufacturing in Michigan Accelerates Ondas' Delivery Timelines for Major Programs, Secures Domestic Supply Chains Resilience, Opens Doors to Growing Opportunities in U.S. Defense and Security Markets with NDAA-Compliant, Made-In-America Drones, and Strengthens Export Readiness to U.S. Allies
Detroit Manufacturing Systems (DMS) Brings Industrial Scale Proven Excellence in U.S. Manufacturing with Speed, Cost Efficiency, and Resiliency
Partnership is Expected to Benefit from Policies Outlined in the Trump Administration's Recent Unleashing American Drone Dominance Executive Order
Working Together, Ondas and DMS Aim to Ensure the U.S. Leads the World in Autonomous Drone Manufacturing, Deployment, and Regulatory Innovation
SPARKS, MD / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 25, 2025 / <a href="https://pr.report/bspk">Ondas Holdings Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) ("Ondas" or the "Company"), a leading provider of private industrial wireless networks and commercial drone and automated data solutions, announced today that its Ondas Autonomous Systems ("OAS") business unit's American Robotics subsidiary has entered into a Letter of Intent for a strategic partnership with <a href="https://pr.report/bspl">Detroit Manufacturing Systems</a> ("DMS") to support the U.S.-based manufacturing and supply chain operations of its autonomous drone platforms. All manufacturing and assembly to take place through DMSs' advanced manufacturing operations, Kinetyc, in Wixom, Michigan, leveraging high quality American production.
Under the agreement, DMS will serve as American Robotics' contract manufacturer and supply chain manager for both U.S. and export markets, significantly enhancing American Robotics' ability to scale production and deliver its FAA Type Certified autonomous drone platforms with greater speed, cost efficiency, and resiliency.
This announcement comes in concert with President Trump's recent <a href="https://pr.report/bspm">Unleashing American Drone Dominance</a> Executive Order designed to bolster U.S. leadership in drone innovation and industrial revitalization. The Executive Order is expected to unlock major investment cycles in the domestic drone sector by supporting critical infrastructure protection, workforce development, and reshoring of advanced manufacturing. The Ondas-DMS partnership aligns directly with these policy objectives by strengthening the American industrial base for dual-use autonomous systems.

ONDS

Ondas Partners With Detroit Manufacturing Systems To Boost U.S. Drone Production

Jefferies analyst Philippe Houchois upgrades Stellantis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) from Hold to Buy and raises the price target from $10.25 to $13.2.

Upgrades

STLA

Jefferies Upgrades Stellantis to Buy, Raises Price Target to $13.2

After a tense showdown following President Donald Trump's decision to use U.S. forces to<a href="https://www.benzinga.com/news/politics/25/06/46043708/us-airstrike-on-iran-draws-varied-reactions-from-business-leaders-bill-ackman-says-thank-you-to-our"> bomb key Iranian nuclear sites</a>, another twist in the geopolitical narrative shines the spotlight on gold. When Israel initially launched an attack against Iran, the precious metals market soared as investors sought a reliable safe haven. However, a<a href="https://www.benzinga.com/trading-ideas/movers/25/06/46082397/oil-prices-tumble-as-israel-iran-ceasefire-takes-shape-for-now"> U.S.-brokered ceasefire</a> between the two warring nations sapped momentum, sending gold and the associated mining complex lower.
Still, investors banking on the cynical angle might not have to wait indefinitely. Although Trump earlier announced the ceasefire on Truth Social, claiming that both sides had agreed to phase out hostilities, the matter wasn't so simple. For instance, Israel's defense minister<a href="https://www.benzinga.com/news/events/25/06/46068524/israel-says-iran-broke-trump-ceasefire-orders-high-intensity-strikes-on-tehran"> accused Iran of violating terms</a> following the detection of missile launches from Iranian territory. As analysts noted, the ceasefire – while encouraging – is fragile.
It&#8217;s important to note that the region supplies nearly one-third of the world's oil. As such, renewed tensions could easily cause both geopolitical and economic disruptions. Under this scenario, precious metal prices may rise, which could lift gold miners.
Moreover, even leaving aside the Israel-Iran conflict, gold has been one of the strongest asset classes. Prior to the hostilities, the metal<a href="https://www.benzinga.com/government/regulations/25/04/44903750/gold-price-soars-to-record-highs-eyes-best-2-month-rally-since-2011-on-blockbuster-etf-buying"> soared to record highs</a> in April, a beneficiary of strong inflows into gold-focused exchange-traded funds. Plus,<a href="https://www.benzinga.com/personal-finance/financial-advisors/25/06/46043344/why-are-central-banks-still-stockpiling-gold"> central banks have been getting in on the action</a>, stockpiling gold amid broader economic and monetary concerns.
Still, not every factor is positive for gold. On the immediate front, if the ceasefire holds and leads to more sustained stability in the Middle East, this dynamic would dampen the metal's risk premium. Potentially, corrective forces could drop the price to prior technical support levels.
On another important note, Federal Reserve Chair Jerome Powell has been<a href="https://www.youtube.com/watch?v=dey0Q0MGmG8"> reluctant</a> to ease monetary policy, choosing instead to adopt a wait-and-see mode. Recently, the Fed chair has been under<a href="https://www.benzinga.com/personal-finance/management/25/06/46011739/jerome-powell-led-fed-has-left-interest-rate-unchanged-what-does-it-mean-for-savings-mortgages-credit-cards-and-your-bank-account"> increasing pressure</a> from the Trump administration to reduce the benchmark interest rate.
The Direxion ETFs: With the safe-haven asset seemingly at a crossroads, traders interested in playing the short-term game may consider Direxion's gold-mining-focused ETFs. For the optimists, the <a href="https://www.direxion.com/product/daily-gold-miners-bull-bear-2x-etfs?utm_source=Referral&amp;utm_medium=Native&amp;utm_source_platform=Benzinga&amp;utm_campaign=LandI_Product_NUGT-DUST">Direxion Daily Gold Miners Index Bull 2X Shares</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUGT#NYSE">NUGT</a>) seeks the daily investment results of 200% of the NYSE Arca Gold Miners Index. On the flipside, the <a href="https://www.direxion.com/product/daily-gold-miners-bull-bear-2x-etfs?utm_source=Referral&amp;utm_medium=Native&amp;utm_source_platform=Benzinga&amp;utm_campaign=LandI_Product_NUGT-DUST">Direxion Daily Gold Miners Index Bear 2X Shares</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUST#NYSE">DUST</a>) seeks 200% of the inverse performance.
Primarily, the Direxion ETFs offer a convenient mechanism for speculation. Ordinarily, those interested in leverage or short positions must engage the options market. However, derivative financial instruments may carry unique complexities that may not suit every investor. In contrast, Direxion ETFs can be bought and sold like any other publicly traded security, thereby mitigating the learning curve.
Still, prospective participants must be aware of the risks that these financial vehicles present. First, leveraged and inverse funds tend to be far more volatile than standard ETFs that track benchmark indices. Second, Direxion ETFs are designed for exposure lasting no longer than one day. Holding beyond the recommended period may lead to value decay due to the daily compounding effect.
The NUGT ETF: While the NUGT ETF has struggled in recent sessions, overall, it has been an outstanding performer, gaining nearly 111% since the start of the year.
<ul class="wp-block-list">
<li>The latest volatility in the NUGT ETF has dropped the price action just below the 20-day exponential moving average but above the 50 DMA.</li>
<li>Since late December to early January, NUGT has generally charted a series of higher highs and higher lows. Unless NUGT falls materially below the 50 DMA, it may not be time to panic.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1002" height="628" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25084715/image-382.png" alt="" class="wp-image-961580" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25084715/image-382.png 1002w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25084715/image-382-300x188.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25084715/image-382-768x481.png 768w" sizes="(max-width: 1002px) 100vw, 1002px" /></figure>
The DUST ETF: On the other end of the scale, the DUST ETF has been a strong performer recently but has lost nearly 64% on a year-to-date basis.
<ul class="wp-block-list">
<li>Problematically, the DUST ETF's price action has been consistently stymied by the 50 DMA, which has acted as resistance.</li>
<li>What's interesting is that Tuesday's price action has been met with strong volume. If the bears can build support, the inverse fund may target the 50 DMA, which stands at $27.37.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1001" height="630" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25084715/image-382.png" alt="" class="wp-image-961581" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25084715/image-382.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25084715/image-382-300x189.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25084715/image-382-768x483.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></figure>
Featured image by <a href="https://pixabay.com/users/istara-200137/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=295938">istara</a> on <a href="https://pixabay.com/photos/gold-gold-bar-gold-bullion-295938/">Pixabay</a>.

Long Ideas

Short Ideas

Technicals

Trading Ideas

ETFs

DUST

NUGT

Geopolitical Whiplash Boosts Profile Of Direxion's Gold-Focused NUGT, DUST ETFs

Aterian, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>), a consumer products company, today announced the expansion of its presence on Mercado Libre, Latin America's leading e-commerce platform. Building on its 2024 launch on Mercado Libre's Mexico marketplace, Aterian began offering select products from its PurSteam, Mueller, and Squatty Potty brands on Mercado Libre's platforms in Chile, Colombia, and Argentina during the second quarter of 2025 reflecting a continued focus on categories such as home, kitchen, and wellness.

Global

ATER

Aterian Expands Mercado Libre Presence To Chile, Colombia, And Argentina With Key Consumer Brands

BMBL

Bumble share are trading higher after the company announced it is reducing the size of its team.

Playboy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) (the "Company" or "Playboy"), a leading pleasure and leisure lifestyle company and one of the most recognizable and iconic brands in the world, today announced that it has legally completed its corporate name change from PLBY Group, Inc. to Playboy, Inc.
The new corporate name aligns the Company's flagship Playboy brand with its corporate name and better reflects the current and future focus of the Company's business operations around the Playboy brand.
The Company's common stock will continue to trade on Nasdaq under the ticker symbol "PLBY", and no change has been made to the CUSIP number for the Company's common stock. As previously announced, the name change was approved by the Company's stockholders at its 2025 annual meeting. The name change does not affect the rights of the Company's stockholders, and stockholders will not be required to take any action in connection with the name change.

PLBY

Playboy Completes Corporate Name Change From PLBY Group, Inc. To Playboy, Inc.

Contango ORE, Inc. ("Contango" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTGO#NYSE">CTGO</a>) is pleased to announce that the Peak Gold JV made a cash distribution in the amount of $21 million ("M") to Contango on June 25, 2025, totaling $54 M to Contango's account received year-to-date. The Peak JV has completed the second of four campaigns in 2025, producing approximately 36,000 ounces of gold for Contango's account year to date, with the third campaign scheduled to commence in August 2025.
Rick Van Nieuwenhuyse, the Company's President and CEO stated, "Guidance for our 30% share of the Peak Gold JV's 2025 production remains at 60,000 ounces of gold, with life-of-mine average annual production expected to be 58,750 ounces of gold per year to 2029 with all-in sustaining costs ("AISC") estimated at $1,400 per ounce of gold sold. In the first week of July, we plan to early pay $7 M of principal against the credit facility, reducing the balance to $23M. In addition, we have early delivered 11,900 ounces of gold into the July 31st hedge contracts using a carry trade, bringing our current hedge contract balance down to 62,900. We anticipate the remaining hedges at the end of 2025 to be 43,000 ounces. Second quarter financial results will be released in early August 2025."
Mr. Van Nieuwenhuyse continued, "Based on year-to-date results and projections going forward, we now expect cash distributions for 2025 from the Peak Gold JV to be in excess of $95 M, assuming a $3,100 per ounce spot gold price for the remainder of 2025. This higher-than-expected cash flow will be used to strengthen our cash position, reduce debt and fulfill our hedge contracts while we continue to advance permitting activities on the Johnson Tract project."

Treasuries

CTGO

Contango Ore Announces That The Peak Gold JV Made A Cash Distribution Of $21M To Contango On June 25, 2025, Totaling $54M To Contango's Account Received Year-To-Date.

General

CORRECTION: Bumble Shares Are Trading Higher

<a href="https://www.globenewswire.com/Tracker?data=Op8f-CK5pOlv-NlsQ3_NpVUDnAksnDvaDpwv3PEa9EyIC_j2s5c6oXaU80N-XNH0f0-lIuY7dB9Hx-dN4kA7YymRnJ34-oBTvsUZrs1ha7Y=">FAST TRACK GROUP</a> (NASDAQ:<a href="https://www.benzinga.com/stock/FTRK#NASDAQ">FTRK</a>) ("Fast Track" or the "Company"), a leading entertainment-focused event management and celebrity agency company, today issued the following statement in response to recent misinformation circulating on social media platforms, including multiple posts on X (formerly Twitter), falsely claiming that the Company is undertaking a $37 million registered direct offering.
Fast Track is aware of recent posts on social media and denies any claims that it is conducting a $37 million registered direct offering as of June 25, 2025. These statements are false and without merit. As of June 25, 2025, the Company has not announced, filed for, or entered into any such offering. The Company urges the public to rely only on official Company communications made through appropriate Regulation Fair Disclosure channels, such as press releases and filings with the U.S. Securities and Exchange Commission (SEC), for the most accurate and up-to-date information.

Offerings

Management

FTRK

Fast Track Group Denies False Social Media Claims Of $37M Stock Offering; Says "These Statements Are False And Without Merit"

Cereal Giant General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) shares dipped in premarket trading Wednesday after the company posted mixed fourth-quarter results and <a href="https://www.benzinga.com/pressreleases/25/06/b46091246/general-mills-reports-fiscal-2025-fourth-quarter-and-full-year-results-and-provides-fiscal-2026-ou" target="_blank" rel="noreferrer noopener">issued a cautious full-year outlook</a>.
The global packaged food company registered quarterly adjusted earnings per share of 74 cents, beating the analyst consensus estimate of 71 cents. Quarterly sales of $4.56 billion (down 3% year over year) missed the Street view of $4.59 billion.
Organic net sales fell 3%, as expected, including a 2-point hit from unfavorable trade expense timing.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44939726/rfk-jr-will-phase-out-artificial-food-dyes-by-end-of-2026-what-it-means-for-pepsi-coca-cola-general-mills" rel="noreferrer noopener">RFK Jr. Will Phase Out Artificial Food Dyes By End Of 2026: What It Means For Pepsi, Coca-Cola, General Mills</a>
Quarterly net sales for General Mills&#8217; North America Retail segment were down 10% to $2.6 billion,&nbsp;North America Pet segment were up 12% to $675 million, North America Food service segment were down 2% to $579 million, and International segment were up 11% to $739 million.
Adjusted gross margin was down 220 basis points to 32.7% of net sales, driven primarily by higher input costs and unfavorable net price realization and mix.
Unfavorable trade expense timing was a 150-basis point headwind to adjusted gross margin in the quarter.
Adjusted operating profit of $622 million was down 22% in constant currency, driven by lower adjusted gross profit dollars. Adjusted operating profit margin was down 330 basis points to 13.7%.&nbsp;
&#8220;Our number one goal in fiscal 2026 is to restore volume-driven organic sales growth,&#8221; said General Mills Chairman and Chief Executive Officer Jeff Harmening.
&#8220;To do that, we&#8217;ll invest further in consumer value, product news, innovation, and brand building, guided by our remarkable experience framework and highlighted by Blue Buffalo&#8217;s national launch into fresh pet food coming later in calendar 2025.&#8221;
The company exited the quarter with cash and equivalents worth $363.9 million and inventories worth $1.91 billion.
General Mills launched a multi-year global transformation initiative under its Accelerate strategy to streamline operations and enhance agility through new tools, technologies, and operating models.
The initiative, along with other efficiency efforts, is expected to deliver $100 million in incremental cost savings in FY2026.
The company declared a quarterly dividend of 61 cents per share, payable August 1, 2025, to shareholders of record July 10, 2025. This represents a 2% increase from the previous quarterly rate.
General Mills expects its fiscal 2026 adjusted diluted EPS to decline 10%-15% in constant currency from the fiscal year 2025 base of $4.21. The company projects organic net sales to range between a 1% decline and a 1% increase.
&#8220;With a clear framework centered on remarkability and positive early returns from our fourth quarter investments, I&#8217;m confident our fiscal 2026 plans will put us on a path back to driving long-term growth in line with our shareholder return model,&#8221; the CEO added.
Price Action: GIS shares are trading lower by 4.51% to $51.00 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45980305/kraft-heinz-bans-artificial-colors-in-us-products-eyes-full-phaseout-by-2027" target="_blank" rel="noreferrer noopener">Kraft Heinz Bans Artificial Colors In US Products, Eyes Full Phaseout By 2027</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

Movers

Cereal Giant General Mills' Cautious Outlook Offers Little Crunch, Stock Falls

Canaccord Genuity analyst Jason Tilchen initiates coverage on Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announces Price Target of $330.

Initiation

FLUT

Canaccord Genuity Initiates Coverage On Flutter Entertainment with Buy Rating, Announces Price Target of $330

Strong Booking Momentum Expected to Continue Through the Second Half of the Year
LETHAM, Scotland, June 25, 2025 /PRNewswire/ --&nbsp;MDJM LTD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UOKA#NASDAQ">UOKA</a>) (the "Company" or "MDJM"), an integrated global culture-driven asset management company, today announced substantial operational growth at its cultural property, Robin Hill Hotel in Torquay, England. The strong performance reflects the Company's ongoing strategic initiatives to enhance guest experiences through immersive cultural programming and elevated dining offerings.
As of June 20, 2025, Robin Hill Hotel has received full-year bookings totaling 911 room nights, compared to 227 total room nights booked in all of 2024, representing a 301% increase. The average daily rate (ADR) has also improved significantly—from £135 to £162, reflecting a 20% increase in average pricing. The Company expects continued growth as the summer peak and holiday seasons approach.

UOKA

MDJM Reports 301% Surge In Full-Year Bookings As Of June 2025 Compared To Total Bookings In 2024

Intelligent Bio Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) ("INBS" or the "Company"), a medical technology company delivering intelligent, non-invasive drug screening solutions, today announced the success of its ongoing partnership with Spjotgard, an established distributor serving the Scandinavian market. The collaboration is accelerating the adoption of the Intelligent Fingerprinting Drug Screening System across Sweden, Norway, and Denmark, with a growing interest in Finland.
Spjotgard, founded in 2021 by a team with deep pharmaceutical expertise, has rapidly developed a strong regional footprint, positioning INBS' fingerprint drug testing technology as its flagship solution in response to rising demand for modern, dignified approaches to drug testing.

Intelligent Bio Solutions Inc. - Common Stock

INBS

Intelligent Bio Solutions Sees Accelerated Nordic Adoption Of Fingerprint Drug Testing Through Spjotgard Partnership

--Data demonstrates that rapid genomic testing dropped the average time to a precise genetic diagnosis from almost ten months to 13 days
--Despite broad utilization in the study, rapid genomic sequencing in non-critical care inpatients yielded a diagnostic rate over 42%, comparable to critical care settings
--Study supports broader adoption of rapid genomic testing in the non-critical care inpatient setting to improve pediatric patient outcomes and lower healthcare costs
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.genedx.com&amp;esheet=54281931&amp;newsitemid=20250625305855&amp;lan=en-US&amp;anchor=GeneDx&amp;index=1&amp;md5=f8f6eb06d0a65b08d3cd94cc3f8b5e24">GeneDx</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), a leader in delivering improved health outcomes through genomic insights, today announced new data from the SeqFirst study team conducted in partnership with the clinical genetics team at Seattle Children's supporting the application of rapid exome sequencing (rES) and rapid genome sequencing (rGS) as a first-tier test for non-critical pediatric inpatients. The study assessed the impact of using rES/rGS as a first-tier test for children receiving genetic consults in non-critical care settings. The researchers examined diagnostic rates before and after a new policy allowing rES/rGS as a first-tier test was implemented. An analysis published in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.jpeds.com%2Farticle%2FS0022-3476%252825%252900240-9%2Ffulltext&amp;esheet=54281931&amp;newsitemid=20250625305855&amp;lan=en-US&amp;anchor=The+Journal+of+Pediatrics&amp;index=2&amp;md5=6f52548a072da7a293f550e48149366a">The Journal of Pediatrics</a> showed that rapid genome testing dropped the average time to a precise genetic diagnosis from almost ten months to less than two weeks.
"Pediatric inpatients often remain undiagnosed and stuck in limbo without answers or treatment as their conditions worsen and costs rise for way too long," said Mike Bamshad, MD, FACMG, Professor of Pediatrics at the University of Washington School of Medicine and Division Chief of Genetic Medicine at Seattle Children's. "The study demonstrated how a policy change allowing for rapid genomic testing as a first-tier test significantly reduced the time to diagnosis in non-critical care pediatric wards, enabling patients to receive timely treatments and potential better outcomes."
Implementation of the SeqFirst approach in the clinical setting led to significant reductions in the time to a genetic diagnosis, with the average time dropping from 289 to 13 days following the policy change that enabled rES/rGS to be ordered as a first-tier test in non-critical care pediatric wards. Despite an increase in utilization of rES/rGS, the diagnostic yield remained high, exceeding 40 percent, comparable to rates in critical care settings. The acceleration of diagnoses enables earlier interventions, better care planning, and improved outcomes for children with rare and undiagnosed conditions.
"Access to rapid genomic testing shouldn't be limited by where a child is admitted in the hospital," said Tara Wenger, MD, PhD, FACMG, Professor of Pediatrics at the University of Washington School of Medicine and Associate Medical Director, Inpatient Service at Seattle Children's. "This study shows that when we remove outdated barriers and bring cutting-edge diagnostics to the broader inpatient setting, we can deliver faster answers, reduce uncertainty for families, and ensure more children benefit from the highest standard of genomic care, regardless of their level of acuity."
Additional findings from the study:
<ul>
<li>Providers caring for patients in pediatric inpatient settings are good at recognizing which patients are appropriate candidates for genetic testing, with 91 percent of consults resulting in the geneticist recommending testing.</li>
<li>When rES/rGS is not used, cases may be lost to follow-up, which delays access to testing and therefore a diagnosis.</li>
<li>The rate at which a precise genetic diagnosis was made from the initial encounter was over 3 times higher when rES/rGS was implemented as a first line test.</li>
</ul>
"This study underscores a major opportunity to expand timely, precise genetic diagnoses in non-critical care inpatients, a setting where genomic testing remains underutilized," said Britt Johnson, PhD, FACMG, SVP of Medical Affairs at GeneDx. "As health systems aim to deliver care more efficiently, expanding rES/rGS access across pediatric inpatients should reduce costs, shorten hospital stays, minimize unnecessary procedures, and improve outcomes for patients and families."

Biotech

GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients In The Journal of Pediatrics. Rapid Genomic Sequencing In Non-Critical Care Inpatients Yielded A Diagnostic Rate Over 42%

Mega Matrix Purchases 12 Bitcoins As Part Of Treasury Strategy At Average Price Of ~$105,554 Per Bitcoin

Press Releases

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Announces Leadership Transitions

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

Comments

Repare Therapeutics

ニュース

最新ニュース Repare Therapeutics (NASDAQ:RPTX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル